Challenges of drug resistance in the management of pancreatic cancer

Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma

(2010) Sally Arai et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Dihydroartemisinin inactivates NF-κB and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo

(2010) Shuang-Jia Wang et al.   CANCER LETTERS

MicroRNA-21 in Pancreatic Cancer: Correlation with Clinical Outcome and Pharmacologic Aspects Underlying Its Role in the Modulation of Gemcitabine Activity

(2010) Elisa Giovannetti et al.   CANCER RESEARCH

Gemcitabine and Vinorelbine Combination in Platinum-Sensitive Recurrent Ovarian Cancer

(2010) Annamaria Ferrero et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)

(2010) Hedy Lee Kindler et al.   JOURNAL OF CLINICAL ONCOLOGY

Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer

(2010) David Cunningham et al.   NEW ENGLAND JOURNAL OF MEDICINE

Economic evaluation of capecitabine as adjuvant or metastatic therapy in colorectal cancer

(2010) Jennie H Best et al.   Expert Review of Pharmacoeconomics & Outcomes Research

Hereditary pancreatic cancer: A clinical perspective

(2009) Julia B. Greer et al.   BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY

Glycogen synthase kinase-3 inhibition disrupts nuclear factor-kappaB activity in pancreatic cancer, but fails to sensitize to gemcitabine chemotherapy

(2009) Shadi Mamaghani et al.   BMC CANCER

Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors

(2009) Yun Jung Choi et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Downregulation of nuclear factor-κB p65 subunit by small interfering RNA synergizes with gemcitabine to inhibit the growth of pancreatic cancer

(2009) Rui Kong et al.   CANCER LETTERS

Acquisition of Epithelial-Mesenchymal Transition Phenotype of Gemcitabine-Resistant Pancreatic Cancer Cells Is Linked with Activation of the Notch Signaling Pathway

(2009) Z. Wang et al.   CANCER RESEARCH

Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer

(2009) T. Arumugam et al.   CANCER RESEARCH

Human Equilibrative Nucleoside Transporter 1 and Human Concentrative Nucleoside Transporter 3 Predict Survival after Adjuvant Gemcitabine Therapy in Resected Pancreatic Adenocarcinoma

(2009) R. Marechal et al.   CLINICAL CANCER RESEARCH

Systemic Therapy of Advanced Urothelial Cancer

(2009) Ulka Vaishampayan   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study

(2009) Miriam Koopman et al.   EUROPEAN JOURNAL OF CANCER

Targeting AKT with the proapoptotic peptide, TAT-CTMP: A novel strategy for the treatment of human pancreatic adenocarcinoma

(2009) Peter O. Simon et al.   INTERNATIONAL JOURNAL OF CANCER

Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer

(2009) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer

(2009) David Cunningham et al.   JOURNAL OF CLINICAL ONCOLOGY

The predictive and therapeutic value of thymidine phosphorylase and dihydropyrimidine dehydrogenase in capecitabine (Xeloda)-based chemotherapy for head and neck cancer

(2009) Koichiro Saito et al.   LARYNGOSCOPE

Antisense Inhibition of microRNA-21 or -221 Arrests Cell Cycle, Induces Apoptosis, and Sensitizes the Effects of Gemcitabine in Pancreatic Adenocarcinoma

(2009) Jong-Kook Park et al.   PANCREAS

Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer

(2009) K. P. Olive et al.   SCIENCE

Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer

(2008) C. Andreetta et al.   ANNALS OF ONCOLOGY

Nuclear Factor- B p65/relA Silencing Induces Apoptosis and Increases Gemcitabine Effectiveness in a Subset of Pancreatic Cancer Cells

(2008) X. Pan et al.   CLINICAL CANCER RESEARCH

HMGA1 Is a Molecular Determinant of Chemoresistance to Gemcitabine in Pancreatic Adenocarcinoma

(2008) S.-S. Liau et al.   CLINICAL CANCER RESEARCH

Role of myofibroblasts in innate chemoresistance of pancreatic carcinoma-Epigenetic downregulation of caspases

(2008) Susanne Sebens Müerköster et al.   INTERNATIONAL JOURNAL OF CANCER

Pancreatic stellate cells—role in pancreas cancer

(2008) Max G. Bachem et al.   LANGENBECKS ARCHIVES OF SURGERY

K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

(2008) Christos S. Karapetis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signaling

(2008) I Ischenko et al.   ONCOGENE

ATP-Binding Cassette C Transporters in Human Pancreatic Carcinoma Cell Lines

(2008) Wolfgang Hagmann et al.   PANCREATOLOGY

Perfusion CT: Noninvasive Surrogate Marker for Stratification of Pancreatic Cancer Response to Concurrent Chemo- and Radiation Therapy

(2008) Mi-Suk Park et al.   RADIOLOGY